Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
Sponsor: Beijing Anzhen Hospital
Summary
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Official title: Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6574
Start Date
2024-09-02
Completion Date
2028-06
Last Updated
2024-10-30
Healthy Volunteers
No
Conditions
Interventions
Colchicine Pill
Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Placebo
Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Locations (1)
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China